---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-164545"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:17:25.626974+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vanda Board rejects two unsolicited takeover proposals, citing undervaluation

## Summary
- Cycle Group bid $8.00/share cash; Future Pak offered $8.50-$9.00/share plus CVRs.
- Board determined both proposals substantially undervalue Vanda and not in best interests.
- Board cites robust revenue, strong cash position, and clinical pipeline as intrinsic value.
- No shareholder action required at this time.

## SEC filing metadata
- accession: 0001193125-24-164545
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312524164545/0001193125-24-164545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312524164545/d844822d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-164545
- JSON: https://secwatch.observer/filing/0001193125-24-164545.json
- Plain text: https://secwatch.observer/filing/0001193125-24-164545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.